Skip to content
Clinical Trials – home
Therapeutic area

Metabolism and nutrition disorders – page 20

  • 741 clinical trials
  • 263 recruiting
  • 237 conditions
  • 26 countries

Conditions in this area

237 conditions with trials, the busiest first

Clinical trials in Metabolism and nutrition disorders

741 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

741 clinical trials

Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dexamethasone
  • Sponsor:Moderna Therapeutics Inc.

Obesity

Recruiting

Study on Vitamin D Deficiency Treatment in Obese Children and Adolescents Using Colecalciferol: Comparing Monthly Boluses and Daily Doses

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Colecalciferol
  • Sponsor:Hospices Civils De Lyon

Study on Pregnancy Rates in Women with Polycystic Ovary Syndrome Using Letrozole and Gonadotropins

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Hospital Universitario La Paz

Study on the Effects of Metreleptin for Patients with Partial Lipodystrophy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Metreleptin
  • Sponsor:Chiesi Farmaceutici S.p.A.

Study on the Safety and Effects of Cipaglucosidase Alfa and Miglustat for Children with Infantile-onset Pompe Disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Study on the Effectiveness of Somatostatin Eye Drops for Patients with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Somatostatin
  • Sponsor:Bcn Peptides S.A.

Study on the Safety and Effects of ION356 for Patients with Pelizaeus-Merzbacher Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:2'-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Plp1 Pre-Mrna
  • Sponsor:Ionis Pharmaceuticals Inc.

Study on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Iduronate-2-Sulfatase Fused To A Fc Polypeptide That Binds To The Human Transferrin Receptor
  • Sponsor:Denali Therapeutics Inc.

Study on Gene Therapy GNT0003 for Patients with Severe Crigler-Najjar Syndrome Requiring Phototherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Genethon

Obesity

Recruiting

Study on Semaglutide and Low Energy Diet for Obesity in Adolescents Aged 12-17

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Vestfold Hospital Trust

Study on Long-Term Safety of Inclisiran for Patients with Familial Hypercholesterolemia Who Completed Previous Adolescent Studies

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Study of ISIS 678354 for Patients with Familial Chylomicronemia Syndrome Previously Treated with Volanesorsen

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Isis 678354 Sodium Salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.